by Alexandra Preston, Natural Society:
If you’re a longevity enthusiast, I’ve got some news for you. After all of these years, aging itself is on its way to be officially classified as a disease. Of course, it’s taken decades of improving life expectancy and survival rates due to better living standards and lifestyles, but it is most likely worth the wait.
This could mean that antiaging will be taken more seriously by the health industry and society as a whole, including insurance companies. It may also raise the value of prevention, instead of just waiting for health problems to appear or reach a certain level of severity before treatment.
So, What Happened Exactly?
Two years ago, researchers managed to convince the United States Food and Drug Administration (FDA) to approve a human lifespan study of metformin, which is currently used for blood sugar control. But it may end up being the first drug approved specifically to ‘treat’ aging.
The study, known as the TAME Study (Targeting Aging With Metformin) started up in 2016, aiming to enroll 3,000 people aged 70-80 and study the effects of metformin over 5-7 years. Everyone must be at risk of or have one or more of the following: cancer, heart disease, or dementia. If metformin can delay or prevent these and delay death, the next step is to test it in younger people.
But why Metformin?
High blood sugar and insulin resistance are key factors in aging and other complex, chronic illnesses, such as cardiovascular disease and cancer. But this is not the only way that metformin could fight aging. Metformin works by acting on an enzyme called AMPK (adenosine monophosphate-activated protein kinase), which regulates how cells process energy.
AMPK boosts metabolism, which may aid weight loss by burning more sugar and fat; it improves blood flow and body composition; it aids cell detoxification and renewal; and it has antioxidant, anti-inflammatory effects.